Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$47.31 USD

47.31
2,857,869

+1.13 (2.45%)

Updated Aug 7, 2025 03:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Catalyst (CPRX) Posts Narrower than Expected Loss in Q2

by Zacks Equity Research

Catalyst Pharmaceuticals, Inc. (CPRX) reported narrower than expected loss in Q2 and is focused on the development of its pipeline candidate Firdapse.

    Arpita Dutt headshot

    Forget Bayer, Buy These 3 Drug Stocks Instead

    by Arpita Dutt

    With Bayer (BAYRY) reporting mixed results in the second quarter and lowering its outlook, here is a look at 3 drug stocks which look well positioned.

      Zacks Equity Research

      VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y

      by Zacks Equity Research

      VIVUS reported dismal second-quarter results wherein its loss widened from the year-ago period on lower sales.

        Zacks Equity Research

        Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

        by Zacks Equity Research

        Emergent's (EBS) earnings and revenues miss estimates in Q2. However, revenue increased year-over-year due to product sales and increase in contract manufacturing revenues.

          Zacks Equity Research

          AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2

          by Zacks Equity Research

          AMAG Pharmaceuticals, Inc. (AMAG) posted narrower-than-expected loss and slightly beat revenue estimates in Q2.

            Zacks Equity Research

            Regeneron (REGN) Beats on Q2 Earnings & Sales, Raises View

            by Zacks Equity Research

            Regeneron Pharmaceuticals, Inc. (REGN) reported strong second-quarter results wherein both earnings and sales beat expectations on the back of Eylea sales.

              Zacks Equity Research

              Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q2

              by Zacks Equity Research

              Immune Design (IMDZ) incurred narrower-than-expected loss in Q2. Revenues missed expectations.

                Zacks Equity Research

                BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates

                by Zacks Equity Research

                BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected loss in Q2 and also beat estimates for sales. The biotech also raised its previously issued full year sales outlook.

                  Zacks Equity Research

                  ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up

                  by Zacks Equity Research

                  ImmunoGen's (IMGN) Q2 results report a narrower-than-expected loss with revenue beating the estimates. The company also significantly raises the cash and revenue guidance this quarter.

                    Zacks Equity Research

                    Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise

                    by Zacks Equity Research

                    Dr. Reddy's Laboratories Ltd.'s (RDY) first-quarter fiscal 2018 earnings per American Depositary Share (ADS) declined year over year while sales increased from the year ago quarter.

                      Zacks Equity Research

                      Sanofi (SNY) Q2 Earnings In Line, Sales Lag,'17 View Raised

                      by Zacks Equity Research

                      Sanofi (SNY) Q2 results were mixed as it reported in-line earnings and slightly missed sales expectations. However, the company raised its 2017 earnings guidance.

                        Zacks Equity Research

                        AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact

                        by Zacks Equity Research

                        AbbVie's (ABBV) Q2 earnings surpass estimates with revenues also marginally beating the same. Sales of its lead marketed drug, Humira, rise year over year.

                          Zacks Equity Research

                          Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat

                          by Zacks Equity Research

                          Keryx's (KERX) loss in Q2 was wider than expected but sales beat estimates. The company also raised its 2017 outlook for net U.S. Auryxia product sales.

                            Zacks Equity Research

                            Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat

                            by Zacks Equity Research

                            Alkermes plc (ALKS) incurred narrower than expected loss in Q2 but marginally surpassed sales estimates. The company reiterated its 2017 outlook.

                              Zacks Equity Research

                              Bayer (BAYRY) Q2 Earnings Beat, Sales Miss, Cuts Guidance

                              by Zacks Equity Research

                              Bayer AG (BAYRY) topped earnings but missed sales expectations in Q2. The company also lowered its guidance for full-year 2017.

                                Zacks Equity Research

                                Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View

                                by Zacks Equity Research

                                Bristol-Myers (BMY) reports encouraging second-quarter results, beating both earnings and sales estimates.

                                  Zacks Equity Research

                                  Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View

                                  by Zacks Equity Research

                                  Alexion Pharmaceuticals, Inc. (ALXN) exceeded both earnings and revenue estimates in Q2 and also raised its 2017 guidance.

                                    Zacks Equity Research

                                    Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat

                                    by Zacks Equity Research

                                    Amgen Inc. (AMGN) beat estimates on both earnings & sales in Q2. While Amgen slightly tightened the sales guidance, it raised the earnings outlook backed by its strong performance in the first half.

                                      Zacks Equity Research

                                      Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed

                                      by Zacks Equity Research

                                      Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.

                                        Zacks Equity Research

                                        Merck's Biosimilar Insulin Gets Tentative FDA Approval

                                        by Zacks Equity Research

                                        Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

                                          Arpita Dutt headshot

                                          Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

                                          by Arpita Dutt

                                          Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

                                            Zacks Equity Research

                                            Sarepta & BioMarin Settle Patent Litigation on Exon Skipping

                                            by Zacks Equity Research

                                            Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies.

                                              Zacks Equity Research

                                              Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt

                                              by Zacks Equity Research

                                              Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.

                                                Zacks Equity Research

                                                Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?

                                                by Zacks Equity Research

                                                Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                                                  Zacks Equity Research

                                                  Perrigo Company Gets FDA Approval for Generic Topical Gel

                                                  by Zacks Equity Research

                                                  Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.